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Footprints of antigen processing boost
MHC class II natural ligand predictions
Carolina Barra1† , Bruno Alvarez1†, Sinu Paul2, Alessandro Sette2, Bjoern Peters2, Massimo Andreatta1,
Søren Buus3 and Morten Nielsen1,4*
Abstract
Background: Major histocompatibility complex class II (MHC-II) molecules present peptide fragments to T cells for
immune recognition. Current predictors for peptide to MHC-II binding are trained on binding affinity data,
generated in vitro and therefore lacking information about antigen processing.
Methods: We generate prediction models of peptide to MHC-II binding trained with naturally eluted ligands
derived from mass spectrometry in addition to peptide binding affinity data sets.
Results: We show that integrated prediction models incorporate identifiable rules of antigen processing. In fact, we
observed detectable signals of protease cleavage at defined positions of the ligands. We also hypothesize a role of
the length of the terminal ligand protrusions for trimming the peptide to the MHC presented ligand.
Conclusions: The results of integrating binding affinity and eluted ligand data in a combined model demonstrate
improved performance for the prediction of MHC-II ligands and T cell epitopes and foreshadow a new generation
of improved peptide to MHC-II prediction tools accounting for the plurality of factors that determine natural
presentation of antigens.
Keywords: MHC-II, Binding predictions, Eluted ligands, T cell epitope, Neural networks, Antigen processing,
Machine learning, Mass spectrometry
Background
Major histocompatibility complex class II (MHC-II) mole-
cules play a central role in the immune system of verte-
brates. MHC-II present exogenous, digested peptide
fragments on the surface of antigen-presenting cells, form-
ing peptide-MHC-II complexes (pMHCII). On the cell sur-
face, these pMHCII complexes are scrutinized, and if certain
stimulatory conditions are met, a T helper lymphocyte may
recognize the pMHCII and initiate an immune response [1].
The precise rules of MHC class II antigen presentation
are influenced by many factors including internalization
and digestion of extracellular proteins, the peptide bind-
ing motif specific for each MHC class II molecule, and
the transport and surface half-life of the pMHCIIs. The
MHC-II binding groove, unlike MHC class I, is open at
both ends. This attribute facilitates peptide protrusion
out of the groove, thereby allowing longer peptides (and
potentially whole proteins) to be loaded onto MHC-II
molecules [2, 3]. Peptide binding to MHC-II is mainly
determined by interactions within the peptide binding
groove, which most commonly encompass a peptide
with a consecutive stretch of nine amino acids [4]. Lig-
and residues protruding from either side of the MHC
binding groove are commonly known as peptide flanking
regions (PFRs). The PFRs are variable in length and
composition and affect both the peptide MHC-II bind-
ing [5] and the subsequent interaction with T cells [6–
8]. The open characteristic of the MHC-II binding
groove does not constrain the peptides to a certain
length, thereby increasing the diversity of sequences
that a given MHC-II molecule can present. Also,
MHC-II molecules are highly polymorphic, and their
binding motifs have appeared to be more degenerate
than MHC-I motifs [9–11].
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Considering all the aspects mentioned above, MHC-II
motif characterization and rational identification of
MHC-II ligands and epitopes is a highly challenging and
costly endeavor. Because MHC-II is a crucial player in the
exogenous antigen presentation pathway, considerable ef-
forts have been dedicated in the past to develop efficient
experimental techniques for MHC-II peptide binding
quantification. The traditional approach to quantify pep-
tide MHC-II binding relies on measuring binding affinity,
either as the dissociation constant (Kd) of the complex
[12, 13] or in terms of IC50 (concentration of the query
peptide which displaces 50% of a bound reference peptide)
[14]. To date, data repositories such as the Immune Epi-
tope Database (IEDB) [15] have collected more than
150,000 measurements of peptide-MHC-II binding inter-
actions. Such data have been used during the last decades
to develop several prediction methods with the ability to
predict binding affinities to the different alleles of MHC
class II. While the accuracy of these predictors has in-
creased substantially over the last decades due the devel-
opment of novel machine learning frameworks and a
growing amount of peptide binding data being available
for training [16], state-of-the-art methods still fail to ac-
curately predict accurately MHC class II ligands and T cell
epitopes [17, 18].
Recent technological advances in the field of mass
spectrometry (MS) have enabled the development of
high-throughput assays, which in a single experiment
can identify several thousands of peptides eluted of
MHC molecules (reviewed in [19]). Large data sets of
such naturally presented peptides have been beneficial to
define more accurately the rules of peptide-MHC bind-
ing [20–26]. For several reasons, analysis and interpret-
ation of MS eluted ligand data is not a trivial task.
Firstly, because any given individual constitutively ex-
presses multiple allelic variants of MHC molecules, thus,
the ligands detected by MS are normally a mixture of
specificities, each corresponding to a different MHC
molecule. Secondly, MHC-II ligands can vary widely in
length, and identification of the binding motifs requires
a sequence alignment over a minimal binding core. Fi-
nally, data sets of MS ligands often contain contami-
nants and false spectrum-peptide identifications, which
add a component of noise to the data. We have earlier
proposed a method capable of dealing with all these is-
sues, allowing the characterization of binding motifs and
the assignment of probable MHC restrictions to individ-
ual peptides in such MS ligand data sets [27, 28].
Because naturally eluted ligands incorporate informa-
tion about properties of antigen presentation beyond
what is obtained from in vitro binding affinity measure-
ments, large MS-derived sets of peptides can be used to
generate more accurate prediction models of MHC anti-
gen presentation [20, 21, 25]. As shown recently, generic
machine learning tools, such as NNAlign [9, 29], can be
readily applied to individual MS data sets, which in turn
can be employed for further downstream analyses of the
immunopeptidome [30]. The amount of MHC molecules
characterized by MS eluted ligand data is, however, still
limited. This has led us to suggest a machine learning
framework where peptide binding data of both MS and
in vitro binding assays are merged in the training of the
prediction method [25]. This approach has proven
highly powerful for MHC class I, but has not, to the best
of our knowledge, been applied to MHC class II.
Undoubtedly, antigen processing plays a critical role in
generating CD4+ T cell epitopes presented by MHC
class II molecules. It is assumed that endo- and
exo-peptidase activities, both before and after binding to
the MHC-II molecule, play a key role in the generation
and trimming of MHC class II ligands [31, 32]. However,
the precise rules of MHC class II antigen processing are
poorly understood. Earlier works identified patterns of
protein cleavage in HLA-DR ligands; Kropshofer et al.
found proline at the penultimate N and C terminal pos-
ition [33], and Ciudad et al. observed aspartic acid be-
fore the cleavage site and proline next to the cut sites in
HLA-DR ligands [34]. In contrast, Bird et al. suggested
that endolysosomal proteases have a minor and redun-
dant role in peptide selection leading to the conclusion
that the effect of processing on the generation of anti-
genic peptides is “relatively non-specific” [35]. Given this
context, it is perhaps not surprising that limited work
has been aimed at integrating processing signals into a
prediction framework for MHC-II ligands.
In this work, we have analyzed large data sets of MS
MHC-II eluted ligands obtained from different research
laboratories covering three HLA-DR molecules with the
purpose of investigating the consistency in the data,
quantifying the differences in binding motifs contained
with such MS eluted data compared to traditional in
vitro binding data, defining a new machine learning
framework capable of integrating information from MS
eluted ligand and in vitro binding data into a prediction
model for MHC-II peptide interaction prediction, and fi-
nally evaluating if inclusion of potential signals from
antigen processing is consistent between different data
sets and can be used to boost the performance of
peptide-MHCII prediction models.
Methods
Data sets
HLA class-II peptidome data were obtained from two
recent MS studies. Three data sets corresponding to the
HLA-DRB1*01:01: DR1Ph, DR1Pm [26], and DR1Sm
[24], two to DRB1*15:01: DR15-Ph and DR15-Pm, and
one to the allele DRB5*01:01: DR51 Ph (for details see
Table 1). Here, the data sets with subscript h correspond
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to the data obtained from human cell lines and data sets
with the subscript m to the data obtained from human
MHC-II molecules transfected into MHC-II deficient
mice cell lines. Details on how the data were generated
are provided in the original publications. Note that
DR15 Ph and DR51 Ph data sets were obtained from a
heterozygous EBV-transformed B lymphoblastoid cell
line (BLCL), IHW09013 (also known as SCHU), which
expresses two HLA-DR molecules, HLA-DRB1*15:01
and HLA-DRB5*01:01 (shortened here with the name
DR15/51). The DR1 Ph data set was extracted from a
BLCL culture as well (IHW09004). On the other hand,
DR1 Pm, DR1 Sm, and DR15 Pm data sets were ex-
tracted from HLA transgenic mice, and therefore only
cover the human alleles of interest. These cells are
treated here as monoallelic.
MHC class II peptide binding affinity data was ob-
tained from previous publications [36] for the alleles
DR1 (DRB1*01:01, 9987 peptides), DR15 (DRB1*15:01,
4466 peptides), and DR51 (DRB5*01:01, 4840 peptides).
The MS-derived ligand data sets were filtered using
the GibbsCluster-2.0 method with default settings as de-
scribed earlier [30], to remove potential noise and biases
imposed by some data containing multiple binding spec-
ificities. The details of the binding affinity (BA) and
eluted ligand (EL) data sets are described in Table 1.
NNAlign modeling and architecture
Models predicting peptide-MHC interactions were trained
as described earlier using NNAlign [29, 30]. Only ligands
of length 11–19 amino acids were included in the training
data. Random peptides of variable lengths derived from
the non-redundant UniProt database were used as
negatives. The same amount of random negatives was
used for each length (11 to 19) and consisted of five times
the amount of peptides for the most represented length in
the positive ligand data set. Positive instances were labeled
with a target value of 1, and negatives with a target value
of 0. Prior to training, the data sets were clustered using
the common motif approach described earlier [37] with a
motif length of nine amino acids to generate five partitions
for cross-validation.
Two types of model were trained: one with single data
type (eluted ligand or binding affinity) input, and one with
a mixed input of the two data types. Single models per
each data set and allele were trained as previously de-
scribed with either binding affinity or eluted ligand data as
input [30]. All models were built as an ensemble of 250 in-
dividual networks generated with 10 different seeds; 2, 10,
20, 40, and 60 hidden neurons; and 5 partitions for
cross-validation. Models were trained for 400 iterations,
without the use of early stopping. Additional settings in
the architecture of the network were used as previously
described for MHC class II [30]. Combined models were
trained as described earlier [25] with both binding affinity
and eluted ligand data as input. Training was performed
in a balanced way so that on average the same number of
data points of each data type (binding affinity or eluted
ligand) is used for training in each training iteration.
Novel modifications were introduced to the architec-
ture of NNAlign to better account for specific challenges
associated with MHC class II ligand data. For the net-
work to be able to learn peptide length preferences, a
“binned” encoding of the peptide length was introduced,
consisting of a one-hot input vector of size nine (one
neuron for each of the lengths 11 to 19). In order to
Table 1 Summary of binding affinity (“Binders”) and eluted ligand (“Ligands”) data sets used in this work
Binders
Reference Source Allele L11–19
DR1 BA Jensen et al. [36] DRB1*01:01 9987
DR15 BA Jensen et al. [36] DRB1*15:01 4466
DR51 BA Jensen et al. [36] DRB5*01:01 4840
Ligands
Reference Source Allele Cell Unique GC L11–9 Random
DR1 Ph Ooi et al. [26] DRB1*01:01 Human 5131 4786 3992 38115
DR1 Pm Ooi et al. [26] DRB1*01:01 Mouse 5744 5561 5385 55710
DR1 Sm Clement et al. [24] DRB1*01:01 Mouse 3216 3112 2963 30510
DR15 Ph Ooi et al. [26] DRB1*15:01 Human 2782 1590 1390 12870
DR51 Ph DRB5*01:01 1087 989 9315
DR15 Pm Ooi et al. [26] DRB1*15:01 Mouse 4810 4486 4229 42030
Binders (upper table): data set reference name (“Reference”), data source (“Source”), MHC restriction (“Allele”), and the amount of sequences in the length range of
11 to 19 amino acids (“L11–19”). Ligands (lower table): data set reference name (“Reference”), data source (“Source”), MHC restriction (“Allele”), cell line species
(“Cell”), amount of unique sequences present in the data set before filtering (“Unique”) and after filtering with GibbsCluster (“GC”), quantity of sequences in the
11–19mer range (“L11–19”), number of random negatives sequences added for training (“Random”). Note that the split of the Ooi et al. human data (DR15 Pm/
DR51 Pm) was made using the GibbsCluster as described in the text
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guide binding core identification, a burn-in period was
introduced with a limited search space for the P1 bind-
ing core position. During the burn-in period, consisting
of a single learning iteration, only hydrophobic residues
were allowed at the P1 binding core anchor position.
Starting from the second iteration, all amino acids were
allowed at the P1 position (Additional file 1: Figure S1).
NetMHCII and NetMHCIIpan
NetMHCII version 2.3 [36] and NetMHCIIpan version
3.2 [36], peptide to MHC-II binding affinity prediction
algorithms were employed in this work as a benchmark
comparison for the new proposed model.
Sequence logos
Sequence logos for binding motifs and context informa-
tion were constructed using Seg2Logo tool using
weighted Kulback-Leibler logos and excluding sequence
weighting [38]. Amino acids were grouped by negatively
charged (red), positively charged (blue), polar (green), or
hydrophobic (black).
Performance metrics
In order to assess the performance of our new model,
we employed three different and well-known metrics:
AUC (area under the ROC curve), AUC 0.1 (area under
the ROC curve integrated up to a false positive rate of
10%), and PPV (positive predictive value). AUC is a
common performance measurement for predictive
models, which takes into account the relationship be-
tween true positive rates (TPR) and false positive rates
(FPR) for different prediction thresholds. AUC 0.1 is
similar to AUC but focuses on the high specificity range
of the ROC curve. PPV is here calculated by sorting all
predictions and estimating the fraction of true positives
with the top N predictions, where N is the number of
positives in the benchmark data set. PPV represents a
good metric to benchmark on highly unbalanced data
sets like MS-derived elution data, where we have ap-
proximately ten times more negatives than positives.
Results
Data filtering and motif deconvolution
We first set out to analyze the different MS data sets of
eluted ligands. Data were obtained from two recent publica-
tions: Ooi et al. [26] (termed P) and Clement et al. [24]
(termed S) covering the HLA-DRB1*01:01,
HLA-DRB1*15:01, and HLA-DRB5*01:01 MHC class II
molecules. Data were obtained from either human (termed
h) or HLA-DR transfected mouse (termed m) cell lines.
Using this syntax, DR1 Ph corresponds to the
HLA-DRB1*01:01 data from the human cell in the study by
Ooi et al. (for more details, see the “Methods” section).
Here, we applied the GibbsCluster method with default
parameters for MHC class II to both filter out potential
noise and to identify the binding motif(s) contained in each
data set. The result of this analysis is shown in Fig. 1 and
confirms the high quality of the different ligand data sets. In
all data sets, less than 7% of the peptides were identified as
noise (assigned to the trash cluster), and in all cases,
GibbsCluster did find a solution with a number of clusters
matching the number of distinct MHC specificities present
in a given data set. In this context, the DR15 Ph is of par-
ticular interest, since this data set was obtained from a het-
erozygous cell line expressing two HLA-DR molecules,
HLA-DRB1*15:01 and HLA-DRB5*01:01 (shortened here
as DR15/51 Ph). Consequently, this data set contains a mix-
ture of peptides eluted from both of these HLA-DR mole-
cules. The GibbsCluster method was able to handle this
mixed data set and correctly identified two clusters with dis-
tinct amino acid preferences at the anchor positions P1, P4,
P6, and P9. Moreover, a comparison of the motifs identified
from the different data sets sharing the exact same
HLA-DR molecules revealed a very high degree of overlap,
again supporting the high accuracy of both the MS eluted
ligand data and of the GibbsCluster analysis tool.
Training prediction models on MHC class II ligand data
After filtering and deconvolution with GibbsCluster,
MHC peptide binding prediction models were con-
structed for each of the six data sets corresponding to
the majority clusters in Fig. 1. Models were trained using
the NNAlign framework as described in the “Methods”
section. The eluted ligand data sets (EL) were enriched
with random natural peptides labeled as negatives, as de-
scribed in the “Methods” section. Likewise, models were
trained and evaluated on relevant and existing data sets
of peptide binding affinities (BA) obtained from the
IEDB [15, 36], as described in the “Methods” section.
These analyses revealed a consistent and high perform-
ance for the models trained on the different eluted lig-
and data sets (Table 2). In accordance with what has
been observed earlier for MHC class I [25], the overall
cross-validated performance of models trained on bind-
ing affinity data is lower than that of models trained on
eluted ligand data. Note that this observation is expected
due the very different nature of the binding affinity and
eluted ligand data sets: eluted ligand data are highly un-
balanced, categorized, and prefiltered to remove ligands
not matching the consensus binding motif.
The binding motifs captured by the different models
are shown in Fig. 2. As evidenced by identical anchor
positions (P1, P4, P6, and P9) and virtually identical an-
chor residues, highly consistent motifs were obtained
from the same HLA-DR molecules irrespective of the
source of the peptide (i.e., whether they were obtained
from human or mouse cells, or from different laborator-
ies). This observation to a high degree extended to the
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motifs obtained from binding affinity data, although we
did observe subtle, but consistent, differences between
the binding motifs derived from eluted ligand and pep-
tide binding affinity data, exemplified for instance by the
preference for E at P4 and for D at P6 in the eluted lig-
and motifs for DR1 and DR15, respectively. Such prefer-
ences are absent from the motifs derived from the
peptide binding affinity data. To quantify differences and
statistically compare the core logos shown in Fig. 2, we
performed a correlation comparison of the amino acid
frequency matrices of the binding motif obtained from
the different models. To this end, we extracted the
amino acid frequencies from the binding motifs dis-
played in Fig. 2, and next did a bootstrapped correlation
analysis comparing the amino acid frequency values at
the four anchor positions (P1, P4, P6, and P9) of the
binding core between all pairs of motifs. The results of
this analysis are given in Additional file 1: Figure S2 and
Table S1 and show (as expected from the logo plots of
Fig. 2) that the different motifs obtained from eluted lig-
and data for a given HLA-DR molecule are all highly
similar (and statistically indistinguishable, P > 0.05, Stu-
dent T test), whereas motif obtained from binding affin-
ity data are significantly different (P < 0.001, Student T
test) from those obtained from eluted ligand motifs.
Training a combined prediction model on MHC-II binding
affinity and ligand elution data
Earlier work on MHC class I has demonstrated that the
information contained within eluted ligand and peptide
binding affinity data is, to some degree, complementary
and that a prediction model can benefit from being
trained integrating both data types [25]. Here, we inves-
tigate if a similar observation could be made for MHC
class II. As proposed by Jurtz et al., we extended the
NNAlign neural network model to handle peptides from
both binding affinity and elution assays. In short, this is
achieved by including an additional output neuron to
the neural network prediction model allowing one pre-
diction for each data type. In this setup, weights are
shared between the input and hidden layer for the two
input types (binding affinity and eluted ligand), whereas
the weights connecting the hidden and output layer are
specific for each input type. During neural network
training, an example is randomly selected from either
data set and submitted to forward and back propagation,
Fig. 1 GibbsCluster output for the five eluted ligand data sets employed in this work. For each set, the Kullback-Leibler distance (KLD) histogram
(black bars) is displayed, which indicates the information content present in all clustering solutions (in this case, groups of one to three clusters)
together with the motif logo(s) corresponding to the maximum KLD solution. The upper row gives the results for the DR15/51 data sets; the
lower row for the DR1 data sets. Note that DR15 Ph was obtained from a cell line which expresses two HLA-DR molecules, HLA-DRB1*15:01 and
HLA-DRB5*01:01 (DR15/51)
Table 2 Cross-validation performance of models trained on
binding affinity (BA) or eluted ligand (EL) data
BA single models EL single models
Training set AUC AUC 0.1 Training set AUC AUC 0.1 PPV
DR1 BA 0.84 0.374 DR1 Ph 0.96 0.819 0.773
DR1 Pm 0.986 0.888 0.815
DR1 Sm 0.977 0.851 0.794
DR15 BA 0.843 0.287 DR15 Ph 0.987 0.901 0.85
DR15 Pm 0.989 0.917 0.859
DR51 BA 0.846 0.38 DR51 Ph 0.961 0.759 0.717
For BA (“BA single models”), the training performance is reported in terms of
AUC and AUC 0.1. For EL (“EL single models”), values for AUC, AUC 0.1, and
PPV are displayed. For references on the training sets names and
compositions, refer to Table 1. For information regarding the performance
metrics, see the “Performance metrics” section in the “Methods” section
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according to the NNAlign algorithm. The weight sharing
allows information to be transferred between the two
data types and potentially results in a boost in predictive
power (for more details on the algorithm, refer to [25]).
Models were trained and evaluated in a fivefold
cross-validation manner with the same model
hyper-parameters that were used for the single data type
model. Comparing the performance of the single data type
(Table 2), to the multiple data type models for the different
data sets (Table 3), a consistent improvement in predictive
performance was observed when the two data types were
combined. This is the case, in particular, when looking at
the PPV performance values. Here, the combined model in
all cases has improved performance compared to the single
data type model. This is in line to what we have previously
observed for MHC class I predictions [25].
Constructing the binding motif captured by the differ-
ent combined models (see Additional file 1: Figure S3)
confirmed the findings from the single data type model
Fig. 2 Binding preferences learned by the single NNAlign [29] models trained on binding affinity (BA) or eluted ligand (EL) data. In the top row,
motifs for the DRB1*01:01 allele are shown, with overlined logo plots (right) corresponding to models trained on EL data, and the non-overlined
logo (left) corresponding to the BA trained model. Similarly, binding motifs for DRB1*15:01 and DRB5*01:01 are displayed in the middle
and bottom row respectively, with overlined logos (right) also indicating the EL-trained model preferences, and the non-overlined logo plot (left)
indicating the BA preference. Logos were constructed from the predicted binding cores in the top 1% scoring predictions of 900.000 random
natural peptides for BA and from the top 0.1% scoring predictions for EL
Table 3 Cross-validation performance for the combined
NNAlign models, trained on both binding affinity (BA) and
eluted ligand (EL) data
Training set BA prediction EL prediction
BA EL AUC AUC 0.1 AUC AUC 0.1 PPV
DR1 BA DR1 Ph 0.845 0.385 0.966 0.823 0.781
DR1 Pm 0.843 0.376 0.987 0.893 0.826
DR1 Sm 0.843 0.381 0.98 0.867 0.814
DR15 BA DR15 Ph 0.844 0.288 0.987 0.908 0.855
DR15 Pm 0.846 0.294 0.99 0.917 0.86
DR51 BA DR51 Ph 0.848 0.389 0.956 0.749 0.74
Training set refers to the data set used to train the given model (BA indicated
binding affinity and EL eluted ligand data). For references on the training sets
names and compositions, refer to Table 1. Cross-validated performance values
are reported as AUC, AUC 0.1, and PPV. For more details on these measures,
refer to the “Methods” section. Note that minor variations in the BA
performance values for the same molecule are due to the differences in the
data partitioning in the fivefold cross-validation setup in each case
Barra et al. Genome Medicine           (2018) 10:84 Page 6 of 15
(displayed in Fig. 2), with clearly defined and consistent
binding motifs in all cases, and with subtle differences in
the preferred amino acids at the anchor positions be-
tween motifs derived from the binding affinity and
eluted ligand output value of the models.
We next turned to the issue of accurately predicting
the preferred length of peptides bound to the different
HLA-DR molecules. The MS eluted ligand data demon-
strated a length preference for the two MHC class II
molecules centered on a length around 14–16. Current
prediction models such as NetMHCII and NetMHCII-
pan are not able to capture this length preference and
have in general a bias of assigning higher prediction
values to longer peptides (data not shown). We have
earlier demonstrated that including information about
the peptide length in a framework integrating MS eluted
ligand and peptide binding affinity data allows the model
to capture the length preference of the two data types
[25]. Applying a similar approach to the MHC class II
data, we obtain the results shown in Fig. 3, confirming
that also for class II the models are capable of approxi-
mating the preferred length preference of each molecule.
Lastly, we performed an evaluation across data sets to
confirm the robustness of the results obtained and to re-
veal any unforeseen signal of performance overfitting.
For each data set, we used the two-output model trained
above to predict the other ligand data sets of the same
allotype. Prior to evaluation, all data with a 9mer overlap
between training and evaluation sets were removed. We
observed that, in all cases, models trained on a specific
data set retained high predictive performance for the
prediction of ligands of the same allotype derived from a
different experiment (Table 4). These results confirm the
high reproducibility of the motifs across different cell
lines, as well as the robustness of the prediction models
derived from individual data sets.
Signals of ligand processing
Having developed improved models for prediction of
MHC class II ligand binding, we next analyzed whether
the models could be used to identify signals of antigen
processing in the MS eluted ligand data sets. We hy-
pothesized that information concerning antigen process-
ing should be present in the regions around the N and C
termini of the ligand. These regions comprise residues
that flank the MHC binding core called peptide flanking
regions (PFRs) and residues from the ligand source pro-
tein sequence located outside the ligand (see lower part
of Fig. 4 for a schematic overview).
We speculate that the signals of antigen processing de-
pend, to some degree, on the length of the PFRs on each
side of the binding core. MHC-II ligands are cut and
trimmed by exopeptidases, which operate according to
specific motifs in prioritizing cleavage sites. However, in
Fig. 3 Peptide length preferences learned by the six models trained on binding affinity (BA) and eluted ligand (EL) combined data. For each
model, green traces represent the length histogram of the top 1% scoring predictions for the BA output neuron, on a prediction data set
composed of one million random peptides; red traces refer to the length histogram of the top 0.1% scoring predictions for the EL output
neuron, on the same prediction set; black traces indicate the length distribution of the raw MS data
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the case of short PFRs, the MHC hinders access of the
protease to the ligand, hence preventing trimming of the
residues in close proximity to the MHC [39, 40]. For this
reason, we expect to observe cleavage motifs only in
peptides with sufficiently long PFRs, where the
end-of-the-trimming signal is given by the peptide
sequence rather than by MHC hindrance. To validate
this hypothesis, we identified the PFRs of the ligands in
the DR15 Pm EL data set, as well as three “context” resi-
dues found immediately upstream or downstream of the
ligand in its source protein. To avoid over-estimation of
the performance, the binding core was identified from
Table 4 Independent evaluation of eluted ligand data set in terms of AUC 0.1
Training set Eval set BA
single
BA
combined
EL
single
EL
combined
NetMHCIIpan NetMHCII
BA EL
DR1 BA DR1 Ph DR1 Pm 0.57 0.644 0.839 0.849 0.562 0.585
DR1 Sm 0.573 0.648 0.81 0.813 0.576 0.578
DR1 Pm DR1 Ph 0.498 0.557 0.757 0.754 0.478 0.469
DR1 Sm 0.514 0.549 0.665 0.669 0.519 0.511
DR1 Sm DR1 Ph 0.506 0.556 0.704 0.707 0.481 0.478
DR1 Pm 0.568 0.636 0.824 0.835 0.54 0.57
DR15 BA DR15 Ph DR15 Pm 0.584 0.672 0.869 0.869 0.427 0.58
DR15 Pm DR15 Ph 0.615 0.71 0.888 0.889 0.459 0.583
“Training set” refers to the data sets used to train the given model (BA indicates binding affinity and EL eluted ligand data). For references on the training sets
names and compositions, refer to Table 1. Cross-validated performance values are reported as AUC 0.1. “Eval set” refers to the independent eluted ligand data set
from the same allotype used for evaluation. “BA single” or “EL single” refers to model trained on single data types (BA or EL respectively). “BA combined” or “EL
combined” refers to the eluted ligand prediction output or binding affinity output of models trained on both data types. NetMHCIIpan or NetMHCII refers to
predictions made using the NetMHCIIpan 3.2 [36], and NetMHCII 2.3 [36] publicly available prediction methods
Fig. 4 Processing signals found at N and C terminus positions in the DR15 Pm data set (located at upstream and downstream regions,
respectively), grouped by peptide flanking region (PFR) length. For the upstream part of the ligands (top row), the processing signal is always
centered at the N terminal position, extending three positions beyond the cleavage site (upstream “context,” symbolized as blue bars) and one to
six positions towards the binding core, depending on the PFR length (orange bars). For the downstream region (bottom row), the disposition of
elements is mirrored: the proposed processing signal is centered at C terminus and extends three positions beyond the cleavage site
(downstream “context” region, pink bars) and one to six positions towards the binding core (green bars), depending on the PFR length. Amino
acid background frequencies were calculated using the antigenic source protein of all the ligands present in the data set. Motifs were generated
using Seq2logo, as described in the “Methods” section
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the cross-validated eluted ligand predictions of the
two-output model. The ligands were split into groups
depending on the length of the C and N terminal PFRs,
and sequence logos were generated for each ligand sub-
set using Seq2Logo (Fig. 5).
The results displayed in Fig. 4 clearly confirm the im-
portant role of the MHC in shaping the processing sig-
nal. For both the N and C terminal data sets, we
observe a clear enrichment of proline (P) at the second
position from the ligand terminals only for data sets
where the PFR is longer than two amino acids. This ob-
servation is confirmed from the reanalysis of a data set
of peptide to HLA-DR complexes from the Protein
Data Bank (PDB) previously assembled for benchmark-
ing the accuracy for MHC-II binding core identification
[41]. On this PDB data set, 29% of the entries with a
N-terminal PFR longer than two amino acids contain a
proline at the second position from the N terminal, and
38% of the entries with a C-terminal PFR longer than
two amino acids contain a proline at the second pos-
ition from the C terminal (data not shown). On the
other hand, none of the bound peptides with
N-terminal PFR shorter or equal than two amino acids
contain a proline at the second position from
N-terminal, and only 8% of peptides with C-terminal
PFR shorter or equal than two amino acids exhibit a
proline at the second position from the C-terminal.
To summarize these observations and construct a glo-
bal motif of the processing signal, we combined the first
three C and N terminal residues from all ligands with
PFR length larger than two, together with the corre-
sponding three source protein context residues at either
C or N terminal side of the ligand. The processing signal
at the N and C termini from DR15 Pm is shown in Fig. 5;
processing motifs for all other data sets can be found in
Additional file 1: Figure S4.
The processing motif confirms the strong preference
for proline at the second but last position in the ligand
at both N and C termini, as well as a clear signal of de-
pletion of other hydrophobic amino acid types towards
the terminals of the ligand. This cysteine depletion in
the PFR is likely to be a technological artifact, as cyste-
ines have previously been shown to be underrepresented
in MS-derived peptide data sets [20, 42]. Note also that
this depletion is only observed in the PFRs and not in
the context residues neighboring the N and C termini.
From this figure, it is also clear that processing signals
present in the neighborhood (indicated as “context” in
Fig. 5) of the ligand are very weak. Similar amino acid
preferences were obtained in the processing motifs from
the other data sets (Additional file 1: Figure S4).
Next, we investigated to what degree the processing
signal was consistently identified in all data sets. To do
this, the similarity between any two processing matrices
was estimated in terms of the Pearson’s correlation coef-
ficient (PCC) between the two vectors of 6*20 elements
(6 positions and 20 amino acid propensity scores at each
position). The result of this analysis is shown in Fig. 6 in
terms of a heatmap (the processing matrices from each
data set are included in Additional file 1: Figure S5).
Figure 6 exhibits a clear positive correlation between
the processing motif from all the data sets involved. The
mean PCC score for the matrices in Fig. 6 was 0.77 for
upstream and 0.73 for downstream, with the lowest
PCC = 0.59 (for the DR1 Sm and DR1 Ph pair, upstream)
and the maximum PCC = 0.89 (for DR15 Pm and DR1
Ph, upstream). These results suggest that the processing
signals captured are, to a large degree, MHC- and even
species-independent: the correlation between the two
human and mouse data sets is as high as the correlation
between any two data sets within the same species. To
ensure that the observed correlation is not related to
Fig. 5 Processing signals located at N and C terminal regions in the DR15 Pm data set. For each region, all ligands with PFR length lower than 3
were discarded. Then, the logos were constructed as described in the text by selecting the closest three PFR and context residues neighboring
the N and C termini. For additional details on processing signal construction, refer to Fig. 4
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MS-derived cysteine depletion, we generated the same
correlation matrices removing the cysteine contribution
and observed no major differences (Additional file 1:
Figure S6). These results thus strongly suggest that the
observed signals are related to antigen processing.
Incorporating ligand processing into a combined
predictor
Having identified consistent signals associated with anti-
gen processing, we next investigated whether these signals
could be integrated into one model to boost predictive
performance. The processing signals were incorporated
into the machine learning framework by complementing
the encoding of each ligand with the 3 N terminal context,
3 N terminal peptide, 3 C terminal context, and 3 C ter-
minal peptide residues (see Fig. 5). For peptide binding af-
finity data, the context information was presented to the
neural networks with three wildcard amino acids “XXX”,
corresponding to a vector of zeros. Two models were
trained for each one of the allotypes considered in this
work: one model including and one excluding the context
information, both allowing integration of binding affinity
and eluted ligand data. Prior to training, the complete set
of data (binding affinity and eluted ligands for all three
MHC-II molecules) was split into five partitions using the
common motif approach as described in the “Methods”
section. All model hyper-parameters were identical to the
ones used earlier. The result of this benchmark is shown
in Table 5 and confirms that the inclusion of context leads
to a consistently improved predictive power of the models
for all three data sets.
As an example of the processing signal captured by a
model trained including context information, we con-
structed sequence motifs of the top 1% highest scoring
peptides from a list of one million random natural pep-
tides of length 10–25 and their context, for a combined
model trained on the DR15 Pm data set (Additional file 1:
Figure S7). As expected, the motif contained within the
N and C terminal peptide flanks and context is close to
identical to the motif described in Fig. 5.
T cell epitope prediction using the combined models
Having observed how prediction of naturally processed
MHC ligands benefited from implementing ligand context
features, we next wanted to evaluate if a similar gain could
be observed when predicting T cell epitopes. We down-
loaded all available epitopes of length 14 to 19 (included)
from the IEDB, for the molecules DRB1*01:01,
DRB1*15:01, and DRB5*01:01. After filtering out entries
Fig. 6 Correlation between processing signals found in the six different data sets employed in this work, for upstream and downstream regions.
Each matrix entry displays the Pearson correlation coefficient (PCC) value of two data sets under study. A PCC value of one corresponds to a
maximum correlation, while a PCC value of zero means no correlation. Processing signals used in this figure were generated as explained in
Fig. 5. All observed PCC values are statistically different from random (P < 0.001, exact permutation test)
Table 5 Cross-validation performance for combined NNAlign
models trained on single-allele data sets, with and without
context information
Without context With context
Allele AUC 0.1 PPV AUC 0.1 PPV P value
DRB1*01:01 0.874 0.824 0.893 0.839 < 0.0001
DRB1*15:01 0.931 0.875 0.947 0.892 < 0.0001
DRB5*01:01 0.805 0.76 0.818 0.782 0.0368
“Allele” refers to the combination of all data sets for that given allele used to
train the model. Cross-validated performance values are reported as AUC 0.1
and PPV. P values were estimated using bootstrapping. For more details on
these measures, refer to the “Methods” section
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with post translational modifications and entries lacking
information about the source protein IDs, a total of 557,
411, and 114 epitopes remained for the three DR mole-
cules, respectively. First, we evaluated this panel of epi-
topes in a conventional way: digesting the epitope-source
protein into overlapping peptides with the length of the
epitope, predicting the peptides using the different
models, and calculating the AUC (area under the receiver
operator curve) per source protein-epitope pair, taking
peptides identical to the epitope as positives and all other
peptides in the source protein as negatives. We excluded
from the evaluation data sets negative peptides that shared
a common motif of nine amino acids with the epitope.
Four methods were included in this benchmark: EL (the
eluted ligand prediction value from the model trained on
the combined data without context information), EL +
context (the eluted ligand prediction value from the model
trained on the combined data including context signals),
NetMHCII (version 2.3), and NetMHCIIpan (version 3.2).
This analysis shows, in line with what we observed earlier
for the eluted ligand benchmarks, a consistent improved
performance of the EL model compared to both NetMH-
CII and NetMHCIIpan (Fig. 7a).
The benchmark however also demonstrates a sub-
stantial drop in predictive power of the EL model
when incorporating the context processing signal (EL
+ context). This drop is however expected since the
mapped T cell epitope boundaries are not a product
of natural antigen processing and presentation, but
rather result from screening of overlapping peptides
from a candidate antigen, or by peptides synthesized
based on the results of MHC peptide binding predic-
tions and/or in vitro binding assays. As a conse-
quence, the N and C terminal boundaries of such
epitope peptides do not necessarily contain the pro-
cessing signal obtained from naturally processed li-
gands. However, given that the epitope was
demonstrated to bind to the T cell originally induced
towards a naturally processed ligand, we can assume
that the sequence of the validated epitope and the
original (but unknown to us) naturally processed lig-
and share an overlap at least corresponding to the
MHC-II binding core of the validated epitope. Follow-
ing this reasoning, we redefined the epitope bench-
mark as follows. First, we predicted a score for all
13–21mer peptides within a given source protein
using the EL or EL + context models. Next, we
digested the source protein into overlapping peptides
of the length of the epitope and assigned a score to
each of these peptides corresponding to the average
prediction score of all 13–21mer peptides sharing a
9mer or more overlap with the given peptide (models
where the max score was assigned were also consid-
ered, but gave consistently lower predictive perform-
ance, data not shown). Finally, we calculated as
before an AUC value for the epitope-source protein
pair taking peptides equal to the epitope as positives
and all other peptides as negatives excluding from the
A B
Fig. 7 Predictive performance on a panel of CD4+ T cell epitopes. The boxplots represent the distribution of AUC values over all epitope
evaluation data sets restricted to a given allele comparing the different models. Middle lines in boxes correspond to median values. The height of
the box represents 50% of the data. Whiskers represent 1.5 quartile range (QR) of data, and dots represent outliers of 1.5 of QR. P significance is
calculated from Wilcoxon test. nsP > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P≤ 0.0001. In both benchmarks, an AUC value was calculated for
each epitope/source protein pair by considering peptides identical to the epitope as positives and all other peptides as negatives excluding
peptides with an overlap of at least nine amino acids to the epitope. a Comparison of the combined models developed in this study with
context information (EL + context) and without context (EL) to current state-of-the-art prediction methods trained on binding affinity data only
(NetMHCII-2.3 and NetMHCIIpan-3.2). b Comparison of EL + context and EL in a benchmark where the epitope evaluation set was constructed
using the evaluation strategy accounting for ligand preference described in the text
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evaluation set negative peptides sharing a common
motif of nine amino acids with the epitope. The
benchmark shows a comparable performance of the
EL + context method vs EL method for the alleles
analyzed in the study (Fig. 7b). Possible reasons for
this lack of improved performance of the EL + con-
text model are discussed below.
Discussion
Peptide binding to MHC II is arguably the most se-
lective step in antigen presentation to CD4+ T cells.
The ability to measure (and predict) specific CD4+
responses is crucial for the understanding of patho-
logical events, such as infection by pathogens or can-
cerous transformations. Recent studies have also
highlighted a potential role for CD4+ T cells for the
development of cancer immunotherapies [43–45].
Characterizing peptide to MHC-II binding events has
been a focal point of research over the last decades.
Large efforts have been dedicated in conducting
high-throughput, in vitro measurements of peptide
MHC II interactions [46–48], and these data have
been used to develop methods capable of accurately
predicting the interaction of peptides to MHC II mol-
ecules from the sequence alone [29, 41, 49, 50].
While these approaches have proven highly successful
as guides in the search for CD4 epitopes [51, 52], a
general conclusion from these studies is that MHC II
in vitro binding affinity (whether measured or pre-
dicted) is a relatively poor correlate of immunogen-
icity [53]. In other words, peptide binding affinity to
MHC II is a necessary but not sufficient criterion for
peptide immunogenicity. The same situation holds for
MHC class I presented epitopes. Here, however, pep-
tide binding to MHC I is a very strong correlate to
peptide immunogenicity and can be used to discard
the vast majority (99%) of the irrelevant peptide space
while maintaining an extremely high (> 95%) sensitiv-
ity for epitope identification [25]. For MHC II, recent
studies suggest that the corresponding numbers fall in
the range 80% specificity and 50% sensitivity [36]. For
these reasons, we suggest that other features than
MHC II in vitro binding affinity may be critical for
MHC II antigen presentation. Based on six MS MHC
II eluted ligand data sets, we have here attempted to
address and quantify this statement.
Firstly, we have demonstrated that the MS MHC II
eluted ligand data sets employed in this work (generated
by state-of-the-art technologies and laboratories) are of
very high quality, with low noise levels and allowing very
precise determination of MHC II binding motifs. Over-
all, the obtained binding motifs show overlap with the
motifs identified from in vitro binding affinity data, with
subtle differences at well-defined anchor positions.
Secondly, we demonstrated that high accuracy pre-
diction models for peptide MHC II interaction can
be constructed from the MS-derived MHC II eluted
ligand data, that the accuracy of these models can be
improved by training models integrating information
from both binding affinity and eluted ligand data
sets, and that these improved models can be used to
identify both eluted ligands and T cell epitopes in
independent data sets at an unprecedented level of
accuracy. This observation strongly suggests that
eluted ligand data contain information about the
MHC peptide interaction that is not contained
within in vitro binding affinity data. This notion is
further supported by the subtle differences observed
in the binding motifs derived from eluted ligand and
in vitro binding affinity data. Similar observations
have been made for MHC class I [20, 25]. We at this
point have no evidence for the source of these differ-
ences, but a natural hypothesis would be that they
are imposed by the presence of the molecular chap-
erones (such as HLA-DM) present in the eluted
ligand but absent from in vitro binding assays. An
alternative explanation could be that the eluted pep-
tide ligands reflect peptide-MHC class II stability ra-
ther than affinity: something that would imply that
stability is a better correlate of immunogenicity than
affinity [54].
Thirdly, we analyzed signals potentially associated with
antigen processing. Antigen-presenting cells employ
multiple mechanisms to acquire and process antigens,
making use of multiple proteases to digest the internal-
ized proteins [55]. It is likely that the processing signals
we observed are a combination of the cleavage specific-
ities of several proteases operating in different stages of
the presentation pathway. Looking for consistent pat-
terns, we postulate that such processing signal should be
influenced by the relative location of the peptide binding
core compared to the N and C terminal of the given lig-
and. This is because the MHC II molecule may hinder
the access of the protease, thus preventing trimming of
the residues in close proximity to the MHC [39]. Investi-
gating the data confirmed this hypothesis, and a rela-
tively weak but consistent processing signal (with a
preference for prolines at the second amino acid pos-
ition from the N and C terminal of the ligand) was ob-
served for ligands where the length of the region
flanking the binding core was three amino acids or
more. This observation was found consistently in all data
sets independent of MHC II restriction and host species
(human or mouse).
Lastly, we integrated this information associated
with antigen processing into a machine learning
framework and demonstrated a consistently improved
predictive performance not only in terms of
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cross-validation but also when applied to independent
evaluation data sets covering naturally processed
MHC eluted ligands. However, we do not observe an
improvement of the extended model for prediction of
validated T cell epitopes. There are several possible
reasons for this. In the first place, it is possible that
epitope data have a bias towards current MHC class
II binding prediction and/or in vitro binding assay
methods, since researchers could use these tools to
select which peptides to include in a T cell epitope
screening or to define the MHC restriction element
for a given positive epitope. Secondly, we have
attempted a very simple strategy to assign a predic-
tion score to each epitope. It might be that the con-
clusion is altered if alternative, more sophisticated
mapping strategies were used. Thirdly, the reason
might be biological: the antigen processing pathways
predominantly utilized in cell lines used for ligand
elution experiments which lead to the motifs we iden-
tified might not be the only ones generating T cell
epitopes in vivo, where, e.g., cross-presentation might
play a role. Finally, our prediction model still does
not capture all properties that could determine T cell
epitope immunogenicity. For example, HLA-DM and
DO clearly have a role in regulating which peptides
can be loaded onto MHC II [56, 57]; however, their
contribution cannot be modeled based on existing
data. Also, T cells themselves impose a level of anti-
gen selection through the interaction between the
TCR and the peptide-MHC complex. While ap-
proaches for peptide-MHC targets of TCR are begin-
ning to appear [58], it is still unclear how they can
be integrated in high-throughput approaches for the
prediction of T cell epitopes. Future work is needed
to disentangle these questions.
Conclusions
We have demonstrated how integrating MHC class II
in vitro binding and MS eluted ligand data can boost
the predictive performance for both binding affinity,
eluted ligand, and T cell epitope predictions. To the
best of our knowledge, we have also demonstrated for
the first time how MHC II eluted ligand data can be
used to extract signals of antigen processing and how
these signals can be integrated into a model with im-
proved predictive performance.
Our work is limited to three HLA-DR molecules,
but the framework can be readily extended to add-
itional molecules, once sufficient data become avail-
able. Also, it may become achievable to construct a
pan-specific predictor as has been shown earlier for
MHC class I [25], enabling predictions for any MHC
molecule of known sequence.
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